保加利亚随机，双盲，安慰剂对照伊维菌素研究显示抗COVID-19的阳性结果
根据保加利亚媒体Economic.BG的报道，
研究（EUDRACT2020-002091-12）
涉及招募和招募具有阳性PCR测试且症状发作时间不超过治疗开始前7天的个体。
病人
连续三天每天以400μg/ kg伊维菌素的剂量给予药物，以及每天接受安慰剂的药物。
100位患者
这项随机研究同时包括了Huvemex和安慰剂组。
Results
As reported in Economic.BG, the results reveal that
the study drug accelerated the clearance of the virus (as evidenced by reading of RT-PCR tests) by day 3 and 4 post treatment start date.
The investigators also
observed marked improvement in patient clinical condition for those in the study drug arm based on the WHO 9- category ordinal scale).As compared to placebo,
the participants receiving the ivermectin based drug fared better, statistically than those in the placebo group.Interestingly,
the study sponsors
observed that the ivermectin-based drug appeared associated with the suppression and normalization of important inflammation biomarkers, considered by many scientists as an important indicator of pathological processes associated with COVID-19 disease progression—including D-Dimer and C-Reactive Protein (CRP).The sponsors
shared with Bulgarian press that the study drug on average started to make its positive impact felt.